Browse every startup, VC firm, and investor tracked on DevCuration. 6,041 companies, sorted alphabetically.
AI-native conversational capture device
AI research lab and ChatGPT developer raising largest funding round ever: $122B at $852B valuation; Amazon $50B (with $35B contingent), Nvidia $30B, SoftBank $30B
Runtime trust layer for enterprise AI: traceable agent decisions, verifiable outputs, governed interactions; integrates Temporal, LangChain, AWS, n8n
Cross-border FX infrastructure with stablecoin rails: $45B+ annualized volume, 98% transactions <60min, 100+ institutional players including Yellow Card, Velafi
Verifiable AI compute infrastructure on blockchain: model hosting, secure inference, agent execution with on-chain auditing for DeFi, DePIN, autonomous agents
Custom photonic ASICs (PASICs) on a heterogeneous silicon photonics platform for AI data centers, telecom, sensing, medical, quantum
Telehealth infrastructure company
Premium homeowners insurance platform sold agent-first across 60K+ partners in 24 states; integrates CoreLogic claims and Hosta A.I. property assessments
Open-source unified observability platform combining logs, metrics, traces, and RUM with up to 140x lower storage costs than legacy stacks
AI infrastructure and model-routing platform
OpenTable serves 70,000+ restaurants as AI, loyalty, media, and Canadian expansion turn its booking network into a broader restaurant tech platform.
Operator-funded VC investing personal capital from inception through Series B; no outside investors, no board seats, founded by Flatiron Health team and others
AI-driven autonomous regime-based options trading platform: Volatility Intelligence Engine, next-gen backtesting, Strategy Engine; revenue $224.6K (2023) to $517.4K (2024); 38 patent apps; TradeStation/Market Rebellion integrations
A New York-based private markets platform serving RIAs, family offices, and wealth managers.
AI-powered governance, risk, and compliance platform
Building an enterprise healthcare AI operating system focused on measurable outcomes.
OS for music and performing arts schools: scheduling, billing, communications, marketing; 200K+ active students, 10M+ lessons/year
Gene therapies for inherited retinal diseases; OPGx-LCA5 and OPGx-BEST1 in pivotal track; RDH12, MERTK, RHO behind; tied to Foundation Fighting Blindness and RD Fund
AI-native software-defined RAN with Odyssey platform for open architecture telecom; AI optimization at the edge; Tier 1 operator and defense alignment
Building a permanent capital company that buys American businesses and pairs long-term ownership with Bitcoin treasury strategy.
Building fault-tolerant quantum computers with neutral-atom architectures.
Developing AI compute satellites for AI inference workloads in low Earth orbit.
Billing and revenue automation for AI, SaaS, cloud, fintech, and subscription businesses.
Visual AI platform tracking video content (faces, products, audio, context) as it gets clipped, remixed, and reposted; clients include Dior, Hennessy, Estée Lauder, Disney; public launch March 31 2026
Lower middle market PE since 2011 (formerly HCI Equity Partners) focused on manufacturing, distribution, technician services; sources 1,000+ opportunities/year
AI infrastructure company that converts licensed video game worlds into structured multimodal training data.
Critical minerals investor: Mine Finance Fund IV $2.2B (61% committed at close) plus $1.8B Critical Mineral Consortium with US/Abu Dhabi, $1.2B JV with ADQ, SNB Capital Saudi partnership, $43M Industrial Ventures
Workflow orchestration platform built on Netflix Conductor for microservices, APIs, and agent-driven workflows with durable execution and observability
AI-powered no-code procurement orchestration: connects multiple systems, approvals, supplier onboarding, compliance, contracts; serves 100+ countries with customers including Novartis, Roche, Coca-Cola, Siemens Energy, Bayer, BASF, Thermo Fisher Scientific; 300% YoY growth; cumulative $160M
Building a unified API access and payment layer for AI agents and developers.
Structure-based oral small molecule targeting BK polyomavirus replication for transplant medicine where 0 approved therapies exist; cumulative $36M raised
Autologous neuron replacement therapy for Parkinson’s: patient-derived iPSCs converted to dopaminergic neurons placed in the putamen; Phase 1b/2a underway